Henderson G I, Speeg K V, Roberts R K, Perez A, Schenker S
Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX 78284.
Biochem Pharmacol. 1988 Jul 1;37(13):2667-73. doi: 10.1016/0006-2952(88)90261-4.
Aging and cimetidine may each impair hepatic microsomal drug metabolism. To test if and by what mechanisms advanced age may increase sensitivity to the inhibitory effects of cimetidine, the interaction of these two factors with aminopyrine metabolism in the rat was studied using a correlative approach. Initial studies using the aminopyrine breath test indicated that a 40 mg/kg dose of cimetidine, i.p., impaired the 14CO2 exhaled by up to 76% more in aged (26-month) than in young (3- to 4-month-old) rats. Using an isolated liver perfusion to dissect out hepatic components of this phenomenon, it was found that various doses of cimetidine impaired aminopyrine clearance to a greater degree (P less than 0.05) in aged than in young livers. However, cimetidine metabolism in this system ranged from 36 to 78% less in aged versus young livers (P less than 0.05). Subsequent in vitro studies indicated that microsomes isolated from aged livers also averaged a 76% lower rate of cimetidine metabolism (P less than 0.05). A fixed cimetidine concentration, however, inhibited aminopyrine demethylation to the same degree in aged versus young rats (P less than 0.05). In vivo pharmacokinetics showed an age-related decrease in both aminopyrine and cimetidine systemic clearance. In the young rat the liver contributed about 30% to total systemic clearance of cimetidine. In the aged rat, all clearance was renal. Despite a decrease in glomerular filtration rate, net tubular cimetidine secretion was well-maintained. Despite this, absence of the hepatic component resulted in decreased overall systemic clearance of the drug in aged rats. It is concluded that (1) the aged rat liver exhibits impaired cimetidine metabolism, resulting in decreased overall systemic clearance of the drug despite normal net renal tubular secretion, (2) there is no age-related enhanced sensitivity to cimetidine of the hepatic microsomal oxidizing system using aminopyrine as the probe drug, and (3) the larger inhibition of aminopyrine metabolism in aged rats following various doses of cimetidine is due to decreased overall cimetidine clearance, resulting in higher concentrations of the inhibitor in the liver of aged rats.
衰老和西咪替丁可能各自损害肝脏微粒体药物代谢。为了测试老年是否以及通过何种机制可能增加对西咪替丁抑制作用的敏感性,使用相关方法研究了这两个因素与大鼠氨基比林代谢的相互作用。最初使用氨基比林呼气试验的研究表明,腹腔注射40mg/kg剂量的西咪替丁,老年(26个月)大鼠呼出的14CO2比年轻(3至4个月大)大鼠减少多达76%。使用离体肝脏灌注来剖析这种现象的肝脏组成部分,发现不同剂量的西咪替丁对老年肝脏中氨基比林清除率的损害程度比年轻肝脏更大(P<0.05)。然而,在该系统中,老年肝脏中西咪替丁的代谢比年轻肝脏低36%至78%(P<0.05)。随后的体外研究表明,从老年肝脏分离的微粒体中西咪替丁代谢率平均也低76%(P<0.05)。然而,固定浓度的西咪替丁在老年大鼠和年轻大鼠中对氨基比林去甲基化的抑制程度相同(P<0.05)。体内药代动力学显示,氨基比林和西咪替丁的全身清除率均与年龄相关下降。在年轻大鼠中,肝脏对西咪替丁总全身清除率的贡献约为30%。在老年大鼠中,所有清除均通过肾脏。尽管肾小球滤过率下降,但肾小管西咪替丁的净分泌仍保持良好。尽管如此,老年大鼠肝脏成分的缺失导致药物的总体全身清除率下降。结论是:(1)老年大鼠肝脏中西咪替丁代谢受损,尽管肾小管净分泌正常,但导致药物总体全身清除率下降;(2)以氨基比林作为探针药物,肝脏微粒体氧化系统对西咪替丁不存在与年龄相关的敏感性增强;(3)不同剂量西咪替丁给药后老年大鼠中氨基比林代谢受到更大抑制是由于西咪替丁总体清除率下降,导致老年大鼠肝脏中抑制剂浓度更高。